dependent diabetic patients. The aim of the transplantation given 2-3 cultured and cryopreserved embryonic tissue masses (about 40 000-60 000 islets). was improvement of metabolic control, and thus delaying Blood glucose was measured with the enzymatic (glucose the progression of retinopathy. As the aim of the present oxidase) colorometric test (Diagnosticum test, Diagnosticum study was to access the long-term effect of islet transplantaRt., Budapest, Hungary) on a Hitachi 717 autoanalyser, tion on the progression of diabetic nephropathy, those 2 h after breakfast. C-peptide levels were measured with patients were selected who had been followed and had radioimmunoassay (RIA-coat C-Peptide kit, Byk-Sangtec functioning grafts after 10 years. Ten of the transplanted Diagnostika GmbH, Germany). The lower limit of sensitivpatients met the above criteria. ity, as given by the manufacturer, is 0.03 ng/ml. Before From other insulin-dependent diabetic patients treated at transplantation or at the start of the study, C-peptide was our outpatient department, who also were candidates for measured 6 min after glucagon provocation (1 mg Glucagon islet transplantation, but who had not been transplanted due Novo i.v.). In the transplant group fasting C-peptide was to the lack of suitable grafts, a control group of 27 insulinmonitored during the follow-up. Plasma creatinine was measdependent patients with retinopathy, and sufficient followured with the kinetic Jaffe reaction (HiCo creatinin CREA up, matched for age, diabetes duration, diabetes onset, Boehringer Mannheim GmbH, Germany). The urinary albuincidence of hypertension and degree of albuminuria was min excretion rate was measured with radioimmunoassay selected.
(Pharmacia Albumin RIA 100, Pharmacia Diagnostics AB., At the start of the follow up, the mean age of the transplant Uppsala, Sweden; normal range <25 mg/l; total coefficient group was 33.6±2.7 that of the controls was 35.3±1.5 years.
of variation 7.1%; recovery 99-103%) from collected 24-h The mean age at the onset of diabetes was 13.5±2.3 years samples. Two parallel measurements were done of every in the transplant and 16.8±2.0 years in the control group, specimen, the mean value of which was taken. As a marker mean diabetes duration was 20.1±1.2 and 18.5±1.5 years of diabetes control HbA 1c levels were measured with colorirespectively. The mean body mass index of the transmetry (Reanal-kit, Reanal Rt., Hungary; normal range plant and the control groups were 24.76±0.96 and 4.5-6.5%; coefficient of variation52.5%). b 2 -Microglobulin 23.41±0.5 kg/m2. There were two light smokers ( less than was measured with Pharmacia b-2-micro RIA (Pharmacia 15 cigarettes/day) in the transplant group and four in the Diagnostics AB, Uppsala, Sweden; normal range <0.3 mg/l; control group. C-peptide was absent from the serum of all total coefficient of variation 7%; recovery 94-103%) in the patients before transplantation or the start of the follow up, 24-h urine collection samples. Serum trigliceride was measeven after glucagon stimulation. The male5female ratio of ured with Diagnosticum test (Diagnosticum, Budapest; the two groups was 753 and 16511. None of the above normal range 0.6-2.4 mmol/l ). Serum cholesterol was measparameters showed a significant difference between the two ured with Diagnosticum test (Diagnosticum, Budapest; groups (P<0.05). All patients had retinopathy. In the trans-normal range 1.3-5.2 mmol/l ). The alterations of retinopathy plant group six patients had background retinopathy and were checked by means of colour stereo-ophthalmography four had proliferative retinopathy, in the control group 21 and fluorescence angiography. had background and six had proliferative retinopathy at the All patients and all parameters were checked 2-4 times start of the study. In the transplant group one patient had annually, and the geometric means of the various measurehypertension before transplantation. In the control group ments in 1 year was calculated. The usual method of assessing three patients had hypertension at the start of the study. albuminuria from three urine specimens collected during a Hypertension was defined as systolic and/or diastolic blood short time period was not used, as sufficient patient complipressure above 140/90 mmHg [5] . Blood pressure was meas-ance with such a large number of urine collections for a ured according to the recommendation of Joint National decade could not be expected; however, the yearly 2-4 Committee V with sphyngomanometry [6 ] .
measurements (at least 3 in the year preceding transplantaAll patients were receiving calcium dobesilat for retinopa-tion), the long follow-up period, and the number of patients thy. Hypertensive patients received captopril and furosemide. was expected to counteract the effect of the biological In the transplant group cyclosporin (8 mg/kg body-weight variability of albuminuria sufficiently to make the two groups per day cyclosporin after transplantation, with subsequent comparable. dosage adjustments to keep the serum RIA level in the range A subgroup of the controls who did not have hypertension of 40-60 ng/ml ) was given for 1-2 years. All patients received was examined separately, and also compared to the transrapid-acting insulin (Actrapid MC, Novo) three time daily plant group. before meals and an intermediate insulin (Monotard MC, Statistical analysis was performed using the SAS software Novo) at bedtime as basal insulin (25-40% of the total daily package version 6.12. Repeated measures analysis of variance insulin dose). After human insulin became available, patients was used to study the effects of time and treatment on the were gradually switched to these (Actrapid HMge and glucose level, HbA 1c , insulin requirement, and albuminuria. Insulatard HMge, Novo or Humulin R and Humulin N, Since the distribution of all these variables were skewed to Lilly). Apart from these no other medication was given.
the right, logarithmic transformation was applied prior to At the start, two of the transplant group and five of the the analysis, to achieve a normal distribution. The ANOVA controls had microalbuminuria, the others were normo-performed using the GLM procedure of SAS. The albuminuric. Normoalbuminuria was defined as urinary Huynh-Feldt adjusted F test was used in all cases of the albumin excretion rate <20 mg/min, microalbuminuria as univariate test for within subject effects. Fischer's exact test 20-200 mg/min, macroalbuminuria as >200 mg/min [7] . The was used to study association of variables in contingency fetal pancreatic islets were isolated from human embryos tables. Results are expressed as means±SEM. After islet transplantation C-peptide levels appeared were compatible), the transplantation was performed into the liver through the umbilical vein [9] . Each patient was (0.55±0.07 ng/ml ), and despite their gradual decrease they were still detectable after 10 years (0.25±0.02 ng/ml ) ( Table 1 ). The mean daily insulin requirement of the transplant group decreased from 53.6±2.2 to 35.8±1.2 units (32.01±3.9%) in the first year. Their insulin requirements were significantly (P<0.01) lower than in the control group throughout the follow-up. Although insulin requirements increased gradually during the study period, they were 28.56±3.2% less than before the transplantation even after 10 years of follow up ( Figure 1) . The mean HbA 1c of the transplant group changed from 8.4±0.3 to 6.2±0.2% in the first year and remained stable during the follow-up ( Table 1) . HbA 1c levels of this group were significantly lower (P<0.01) than in the controls throughout the follow up period.
In the transplant group postprandial blood glucose levels decreased from 9.6±0.6 to 6.2±0.2 mmol/l, stayed relatively stable for 10 years, and were significantly (P<0.05) lower than in the control group throughout (Table 1 ). In the transplant patients the frequency of hypoglycaemic episodes causing clinical symptoms was one episode per year, while in the control group it was seven episodes per year.
The mean albumin excretion rate of the two groups are summarized in Figure 2 . Albumin excretion rates were found to be dependent on time, with a significant increase (P<0.01) from the 5th year. From the 6th year a significant difference (P<0.05) was seen between the two groups. In the transplant group there were eight patients with normoalbuminuria and two with microalbuminuria, which did not change during the follow up. In the control group, of the 22 previously normoalbuminurics, 11 remained normoalbuminuric, six progressed to microalbuminuria and five to macroalbuminuria; one of the latter developed azotaemia (creatinine>180 (mmol/l ). Of the five microalbuminurics, two progressed to macroalbuminuria, both of them developing azotaemia, while the other three remained unchanged. During the follow up of the transplant group one new case of hypertension was seen beside the one previously hypertensive patient. In the control group, besides the three previously hypertensive patients, newly diagnosed hypertension developed in eight cases. In the subgroup of the 16 controls without hypertension, out of the 15 previously normoalbuminurics, four progressed to microalbuminuria. One patient with pre-existing microalbuminuria remained at the same stage. In the transplant group mean urinary b 2 -microglobulin levels were 80.1±17.8 mg/l prior to transplantation, with no significant change during cyclosporin administration (81.0±14.9 mg/l in the first and 82.6±15.7 mg/l in the second year). Mean systolic and diastolic blood pressure before the transplantation was 132.0±3.3 and 81.5±1.5 mmHg. In the control group initial mean systolic and diastolic blood pressure values were 130.4±3.4 and 79.6±1.6 mmHg. Neither significant changes of blood pressure during the followup in either group, nor significant differences between the two groups were seen. ( Table 2 ) Mean serum cholesterol was 4.8±0.1 mmol/l in the transplant and 4.8±0.1 mmol/l in the control group initially, and no significant subsequent changes were seen. Mean serum trigliceride was 2.0±0.1 mmol/l in the transplant and 1.7±0.1 in the control group. Serum creatinin and creatinine clearance values are given in Table 3 . Significant differences between the two groups or changes in either group were not observed.
Discussion
It is generally accepted that among other factors, insufficient metabolic control has a major role in the development of late diabetic complications. Effective long-term intensive insulin therapy significantly reduces the risk of diabetic nephropathy and retinopathy, but unfortunately it is accompanied by a higher frequency of hypoglycaemic episodes [1] . Transplantation of the whole pancreas or of isolated pancreas islets prevents and reverses the development of glomerular lesions in diabetic animals [10] . The Diabetes Control and Complications Trial Research Group has reported that improved metabolic control is easier to achieve in patients, who retain endogenous insulin secretion, as determined by connecting peptide levels [1] . Islet transplantation together with insulin therapy may increase the chances of achieving normoglycaemia, perhaps with a lower risk of hypoglycaemia [11] . In our patients the appearance of C-peptide levels proved the insulin production of the allografts, which persisted throughout the follow up period. Our results are similar to the experience of others [4] , and can explain the improved diabetes control and smaller exogenous insulin requirement of the transplanted patients. In the present study insulin independence, occasionally experienced after islet transplantation [4], was not achieved, but recipients had lower exogenous insulin requirements. Although the difference decreased during the course of the follow up, it was still significant after 10 years. The reduction of insulin doses, however, should not in itself be a goal, as hyperglycaemia resulting from the overzealous reduction of exogenous insulin can have an adverse effect on the survival of the transplanted islets [12] .
Transplant patients had significantly lower blood glucose and HbA 1c levels throughout the follow-up period, and this can be one of the factors, that contribute to the nephroprotective effect of pancreatic islet transplantation. Furthermore the ratio between portal and peripheral insulin concentrations is likely to be more favourable in islet transplantation patients than in insulin-dependent diabetics treated with subcutaneous insulin only. This ratio in the transplant group is likely to be closer to the 351 ratio seen in non-diabetic individuals [13] . This may be beneficial, as systemic hyperinsulinaemia is considered to be atherogenic [14] .
Islet transplantation seems to have delayed the development of diabetic nephropathy. In the transplant group no major changes of albuminuria were seen. Although some increase of the albumin excretion rates was experienced, all patients remained in the same stage of abuminuria in which they were before the transplantation. In the control group mean albuminuria increased, and after the fifth year significantly higher mean albumin excretion rates were seen than in the transplant group. Progression to micro-and macroalbuminuria was seen in nearly half of the control patients, with azotaemia developing in some cases. If we compare the transplant recipients to the subgroup of 16 controls who were without hypertension throughout the follow up, the above tendency can still be observed, as in about one-third of the normotensive controls a progression of albuminuria was found. Four of the 15 normoalbuminuric normotensive controls became microalbuminuric. Hypertensive patients received angiotensin-converting enzyme inhibitors, which may have slowed the development of nephropathy [15] . Since the control group had a larger percentage of hypertensive patients, it is unlikely, that the administration of angiotensin-converting enzyme inhibitors could have contributed to the more favourable outcome of the transplant group in terms of albuminuria. 
